Aarey Drugs & Pharmaceuticals share price
NSE: AAREYDRUGSBSE: 524412Pharmaceuticals & BiotechnologySmall Cap
Aarey Drugs & Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1994 on BSE, Aug 2021 on NSE
Last close ₹108.05up ₹1.47 (1.38%)BSE ₹108.40
Share price at the NSE close on 28 Oct 2026. Previous close ₹106.58.
28 Oct: open ₹102.11, high ₹109.70, low ₹102.11
52-week range of traded prices to 28 Oct 2026
₹50.31Low, 30 Mar 2026₹114.80High, 19 Oct 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 28 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹344 Cr2,366th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.33
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,40,50858.3% delivered
Results
Standalone; ₹ crore.Aarey Drugs & Pharmaceuticals quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −7.7%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹45 Crdown 76.45%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹1.02 Crdown 34.27%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 2.3%
Revenue by quarter
Peak revenue ₹189 Cr, quarter to Mar 2026; lowest ₹45 Cr, quarter to Jun 2026
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 105 | 134 | 108 | 102 | 84 | 96 | 189 | 45 |
| Net profit | 2 | 1 | 0 | 1 | 1 | 1 | 2 | 1 |
| Net margin | 1.5% | 0.5% | 0.4% | 1.3% | 1.2% | 0.6% | 0.8% | 2.3% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹472 Crdown 0.35%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹3.97 Crdown 1.40%
- Net margin
- 0.8%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2021, the company's revenue for that year, ₹348 Cr, differs from its quarters added, ₹333 Cr.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 396 | 349 | 355 | 300 | 348 | 493 | – | 396 | 474 | 472 |
| Net profit | 6 | 6 | 7 | 6 | 7 | 8 | – | 5 | 4 | 4 |
| Net margin | 1.5% | 1.8% | 1.8% | 1.9% | 1.9% | 1.5% | – | 1.2% | 0.8% | 0.8% |
Standalone. Years to March. The latest is shaded. No results on record for the year to Mar 2023.
Business segments
In the year to Mar 2026 the company reports one business segment, DRUGS AND PHARMACEUTICALS, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +51.4% | −2.1% | +54.7% | 0.0% |
| 3 years | +28.4% | – | – | 0.0% |
| 5 years | +16.9% | −13.0% | +34.4% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Aarey Drugs & Pharmaceuticals insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade
- Others: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Aarey Drugs & Pharmaceuticals competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Aarey Drugs & Pharmaceuticals in market cap. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Aarey Drugs & Pharmaceuticals is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Haleos LabsHALEOSLABS | 439 | 27.75 | 2.05 | −3.1% | −8.5% | 7.7% | 7.4% | 0.10% |
 Infinium PharmachemINFINIUM | 429 | 35.28 | 3.54 | +21.8% | +41.8% | 10.5% | – | 0.00% |
 Jenburkt PharmaceuticalsJENBURPH | 387 | 11.78 | 1.96 | +9.1% | +1.2% | 17.8% | 19.2% | 2.36% |
 Medicamen BiotechMEDICAMEQ | 358 | – | 1.30 | +24.7% | – | – | 3.7% | 0.39% |
 Astonea LabsASTONEALAB | 340 | 75.19 | 5.94 | – | – | 12.0% | – | 0.00% |
 Astal LaboratoriesASTALLTD | 289 | 29.67 | 0.87 | +122.7% | +4.4% | 5.4% | 4.2% | 0.00% |
 Lyka LabsLYKALABS | 280 | – | 3.03 | −2.6% | – | −9.2% | −8.0% | 0.00% |
 Ambalal Sarabhai EnterprisesAMBALALSA | 272 | 20.09 | 1.72 | +4.9% | +5.8% | 9.1% | 5.0% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Aarey Drugs & Pharmaceuticals announcements
Oct 2026
7 Oct
3 Oct · Disclosure of material issue
3 Oct · Disclosure of material issue
3 Oct · Disclosure of material issue
Sep 2026
30 Sep · Meeting
Aarey Drugs & Pharmaceuticals annual report, year to Mar 2026
Aarey Drugs & Pharmaceuticals share price by year
Each calendar year to 2025.Aarey Drugs & Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 67.67 | +18.5% | 99.25 | 33.51 |
| 2024 | 57.10 | +13.0% | 73.61 | 37.75 |
| 2023 | 50.55 | +30.8% | 53.25 | 22.60 |
| 2022 | 38.65 | −10.0% | 61.25 | 28.80 |
| 2021BSE close | 42.95 | +41.3% | 43.50 | 22.80 |
| 2020BSE close | 30.40 | +34.8% | 40.15 | 12.60 |
| 2019BSE close | 22.55 | −27.4% | 33.15 | 13.05 |
| 2018BSE close | 31.05 | −46.9% | 64.35 | 28.65 |
| 2017BSE close | 58.45 | +19.7% | 130.70 | 46.45 |
| 2016BSE close | 48.85 | +99.4% | 56.60 | 17.45 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 100.13 | 106.95 | 100.13 | 106.58 | 106.01 | 1,56,560 | 52.8% |
| 26 Oct 2026 | 105.99 | 105.99 | 101.40 | 103.19 | 102.88 | 2,35,039 | 62.0% |
| 23 Oct 2026 | 108.10 | 110.64 | 104.89 | 106.73 | 106.38 | 2,92,242 | 74.3% |
| 22 Oct 2026 | 111.93 | 114.00 | 108.01 | 110.41 | 111.29 | 2,08,417 | 74.7% |
| 21 Oct 2026 | 114.00 | 114.70 | 110.00 | 111.93 | 112.25 | 2,37,818 | 81.2% |
| 19 Oct 2026 | 114.80 | 114.80 | 110.00 | 113.87 | 112.30 | 1,99,690 | 57.8% |
| 16 Oct 2026 | 107.01 | 113.50 | 105.21 | 112.91 | 110.61 | 1,87,209 | 66.0% |
| 15 Oct 2026 | 106.96 | 108.96 | 105.00 | 108.74 | 107.64 | 1,41,631 | 62.1% |
| 14 Oct 2026 | 103.10 | 106.95 | 102.00 | 106.32 | 106.10 | 2,09,543 | 74.3% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- AAREYDRUGS
- BSE code
- 524412
- ISIN
- INE198H01019
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.aareydrugs.com
- CIN
- L99999MH1990PLC056538
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1990
- Registered office
- E 34, MIDC, Tarapur, Boisar, Thane 401506, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments